Coupled with our present findings, the SREBP-1c can be a target for nutritional intervention during the process of steatosis and the slowly digestible carbohydrate (i.e. starches high in amylose) may help preventing or treating obesity and non-alcoholic fatty liver disease (NAFLD) in human. This evidence concerns the gene SREBF1 and metabolic dysfunction-associated steatotic liver disease.